The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The Role Of Stellate Cells In Fibrosis And Liver Disease Progression In HIV-Hepatitis B Co-infection
Funder
National Health and Medical Research Council
Funding Amount
$157,292.00
Summary
Liver related mortality is the commonest cause of non-AIDS death in HIV infected individuals on treatment. With HIV, HBV liver damage is accelerated and liver-related mortality increased. Understanding how and why is critical to management. I will examine the role of hepatic stellate cells using in vitro models and directly ex vivo from infected patient biopsy tissue. I will investigate the activated of these cells by HIV and HBV infection, thus promoting scar formation with liver injury.
Personalised Treatment In Melanoma: Matching Optimal Drug Therapies For Individual Patients To Improve Survival.
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
The best treatment for melanoma currently is immunotherapy. However, most patients become resistant to immunotherapy after an initial response. When this occurs, patients are treated with new medications, often in a clinical trial. Unfortunately, doctors cannot predict if a patient is going to respond to a particular new treatment. This project will study the makeup of individual melanomas and use this to recommend which new treatment is most likely to work for the patient.
Clearing Chronic Infectious Diseases – Enhancing Host Immune Effector Function
Funder
National Health and Medical Research Council
Funding Amount
$92,314.00
Summary
Chronic infections produced by pathogens such as HIV, overwhelm our immune system leading to an exhausted state where cells responsible for the clearance of invading microorganisms are unable to respond effectively. We have recently identified a highly promising therapeutic target that enhances immune effector function. We seek to understand the underlying mechanism, and to explore the therapeutic potential of this approach for the treatment of a broad range of pathogens, including those respons ....Chronic infections produced by pathogens such as HIV, overwhelm our immune system leading to an exhausted state where cells responsible for the clearance of invading microorganisms are unable to respond effectively. We have recently identified a highly promising therapeutic target that enhances immune effector function. We seek to understand the underlying mechanism, and to explore the therapeutic potential of this approach for the treatment of a broad range of pathogens, including those responsible for chronic disease.Read moreRead less
Assessing The Utility Of Circulating Cell-free MicroRNA As Biomarkers For Response In A Variety Of Non Hodgkin Lymphomas
Funder
National Health and Medical Research Council
Funding Amount
$92,159.00
Summary
Non Hodgkin Lymphomas are the most common blood cancer to affect adult Australians. The current strategies for diagnosis, treatment and monitoring of these patients are generic and not tailored to features of particular patientÍs lymphoma or treatment response. We aim to develop a new blood based marker for Lymphoma that can be used to diagnose and monitor NHL patients, to allow treatment to be adjusted according the patients current response to therapy, as indicated by the blood based marker. T
Circulating Tumor DNA To Monitor Treatment Response And Resistance In Mantle Cell Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Many cancers shed small amounts of DNA into the patient’s bloodstream. Recent advances in genomic technologies now allow small levels of cancer DNA to be accurately measured in the peripheral blood. Changes in DNA levels have the potential to be used as specific markers of disease progression and/or response to cancer therapy. This project will evaluate if this DNA can be measured from a simple blood test to serially follow patients receiving treatment for mantle cell lymphoma.
Use Of Circulating Tumour DNA To Characterise The Mutational Landscape Of Marginal Zone Lymphoma, Monitor Treatment Response And Detect Emergence Of Resistance
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Marginal zone lymphoma (MZL) is a subtype of B-cell non-Hodgkin lymphoma for which the molecular drivers of disease are poorly understood. We hypothesise that circulating tumour DNA may be ideal for characterising the genetic mutations that underpin MZL, monitoring treatment response and detecting emergence of resistance. This non-invasive method of disease monitoring has the potential to transform management of cancers such as MZL, identify new treatment options and improve survival outcomes.
Understanding the mechanisms in the development of mutations in cancers will assist in development of targeted therapies to overcome chemotherapy resistance. The recently discovered TMPRSS2:ERG fusion in prostate cancer is unique as dominant fusion translocations are uncommon in solid organ malignancy. Activation induced cytidine deaminase (AID) is thought to play a role. Understanding the role of AID and downstream DNA repair pathways may be a target for future therapies in cancer.
The Mechanisms Of SIV Entry Of Follicular Helper T Cells
Funder
National Health and Medical Research Council
Funding Amount
$95,313.00
Summary
Follicular helper T (Tfh) cells are a type of immune cells essential in antibody production. Preliminary data shows that SIV infects macaque Tfh cells. In this project, we will investigate the mechanisms by which SIV enters into Tfh cells, and test the susceptibility of human Tfh cells to HIV-1 infection ex vivo. This project will enable understanding of the fate of Tfh in HIV infection and its role in HIV host defense and it may facilitate the design of vaccine against HIV.
Molecular Dissection Of Cytokine-mediated Regulation Of Human B-cell Differentiation.
Funder
National Health and Medical Research Council
Funding Amount
$119,314.00
Summary
Interleukin 21 is a molecule which activates B cells. Defects in this pathway cause immunodeficiency where individuals cannot make antibodies, while constant activation has been reported in mouse models of autoimmunity. Examining these pathways will shed light on the causes of human immune disease, and may reveal molecules that could be targeted for the treatment of immunodeficiency and autoimmunity. Amplification of normal immune responses could lead to the development of improved vaccines.
Hepatitis B In The Top End Of The Northern Territory: Epidemiology, Burden Of Disease And Health Literacy Among Those Affected.
Funder
National Health and Medical Research Council
Funding Amount
$118,574.00
Summary
I am an Infectious Diseases doctor working with Hepatitis B in the Top End of the Northern Territory. I will provide detailed information about the prevelance of Hepatitis B infection, the specific subtypes found in this region and the burden of disease attributable to it. This information is not currently available for this region. I will also explore the levels of knowledge in the community about Hepatitis B infection using this information to develop and evaluate an educational tool.